Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 1Melanoma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Exanthema 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 112Fluorouracil 98Oxaliplatin 96Leucovorin 96Irinotecan 86Capecitabine 73Cetuximab 64Panitumumab 42pembrolizumab 38regorafenib 28Nivolumab 23IFL protocol 22Folfox protocol 21trifluridine tipiracil drug combination 14Radiotherapy 13durvalumab 11Gemcitabine 10Celecoxib 10tremelimumab 7binimetinib 7aflibercept 7Drug Therapy 7Disulfides 7Cyclophosphamide 7Trifluridine 6Trastuzumab 6Sunitinib 6Paclitaxel 6Immunoglobulin G 6Colonoscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colorectal Neoplasms × Anti-Bacterial Agents × Clear all
NCT01931150 2017-01-13

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
11 enrolled 7 charts
Gastrointestinal

Exanthema, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡